

World Journal of *Gastrointestinal Surgery*

World J Gastrointest Surg 2024 April 27; 16(4): 974-1217



Contents

Monthly Volume 16 Number 4 April 27, 2024

EDITORIAL

- 974 How to identify early complications in patients undergoing distal gastrectomy?
Tropeano G, Chiarello MM, Fico V, Brisinda G
- 982 Quality assessment of surgery for colorectal cancer: Where do we stand?
Morarasu S, Livadaru C, Dimofte GM
- 988 Emerging molecules, tools, technology, and future of surgical knife in gastroenterology
Kumar A, Goyal A
- 999 Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions
Dilek ON, Arslan Kahraman Dİ, Kahraman G
- 1008 Relationship between *Helicobacter pylori* infection and colorectal polyp/colorectal cancer
Liu Y, Yang DQ, Jiang JN, Jiao Y

MINIREVIEWS

- 1017 Near-infrared cholangiography with intragallbladder indocyanine green injection in minimally invasive cholecystectomy
Symeonidis S, Mantzoros I, Anestiadou E, Ioannidis O, Christidis P, Bitsianis S, Bisbinas V, Zapsalis K, Karastergiou T, Athanasiou D, Apostolidis S, Angelopoulos S
- 1030 Blastomas of the digestive system in adults: A review
Liu Y, El Jabbour T, Somma J, Nakanishi Y, Ligato S, Lee H, Fu ZY

ORIGINAL ARTICLE

Retrospective Study

- 1043 Single-center retrospective study of the diagnostic value of double-balloon enteroscopy in Meckel's diverticulum with bleeding
He T, Yang C, Wang J, Zhong JS, Li AH, Yin YJ, Luo LL, Rao CM, Mao NF, Guo Q, Zuo Z, Zhang W, Wan P
- 1055 Prognostic value of a nomogram model for postoperative liver metastasis of colon cancer
Cheng DX, Xu KD, Liu HB, Liu Y
- 1066 Computer-assisted three-dimensional individualized extreme liver resection for hepatoblastoma in proximity to the major liver vasculature
Xiu WL, Liu J, Zhang JL, Wang JM, Wang XF, Wang FF, Mi J, Hao XW, Xia N, Dong Q
- 1078 Research on the prognostic value of adjusting intraperitoneal three-dimensional quality evaluation mode in laparoscopic cholecystectomy patients
Zhou Y, Chen ZQ

- 1087** Construction of a predictive model for acute liver failure after hepatectomy based on neutrophil-to-lymphocyte ratio and albumin-bilirubin score

Li XP, Bao ZT, Wang L, Zhang CY, Yang W

- 1097** Predicting short-term thromboembolic risk following Roux-en-Y gastric bypass using supervised machine learning

Ali H, Inayat F, Moond V, Chaudhry A, Afzal A, Anjum Z, Tahir H, Anwar MS, Dahiya DS, Afzal MS, Nawaz G, Sohail AH, Aziz M

- 1109** Comparative analysis of two digestive tract reconstruction methods in total laparoscopic radical total gastrectomy

Dong TX, Wang D, Zhao Q, Zhang ZD, Zhao XF, Tan BB, Liu Y, Liu QW, Yang PG, Ding PA, Zheng T, Li Y, Liu ZJ

- 1121** Incidence of surgical site infection in minimally invasive colorectal surgery

Ni LT, Zhao R, Ye YR, Ouyang YM, Chen X

Observational Study

- 1130** Burden of gallstone disease in the United States population: Prepandemic rates and trends

Unalp-Arida A, Ruhl CE

Prospective Study

- 1149** Kuicolong-yu enema decoction retains traditional Chinese medicine enema attenuates inflammatory response ulcerative colitis through TLR4/NF- κ B signaling pathway

Han L, Tang K, Fang XL, Xu JX, Mao XY, Li M

SYSTEMATIC REVIEWS

- 1155** Quality-adjusted life years and surgical waiting list: Systematic review of the literature

de la Plaza Llamas R, Ortega Azor L, Hernández Yuste M, Gorini L, Latorre-Fragua RA, Díaz Candelas DA, Al Shwely Abduljabar F, Gemio del Rey IA

META-ANALYSIS

- 1165** Impact of different anastomosis methods on post-recurrence after intestinal resection for Crohn's disease: A meta-analysis

Wang ZZ, Zhao CH, Shen H, Dai GP

CASE REPORT

- 1176** Suspected coexistence of perianal necrotizing sweet syndrome in chronic myelomonocytic leukemia: A case report

Yu KQ, Li HX, Wu J

- 1184** Successful splenic artery embolization in a patient with Behçet's syndrome-associated splenic rupture: A case report

Zhu GZ, Ji DH

- 1189** Stercoral perforation of the cecum: A case report

Yu HC, Pu TW, Kang JC, Chen CY, Hu JM, Su RY

- 1195** Percutaneous transhepatic stenting for acute superior mesenteric vein stenosis after pancreaticoduodenectomy with portal vein reconstruction: A case report
Lin C, Wang ZY, Dong LB, Wang ZW, Li ZH, Wang WB
- 1203** Endoscopic treatment of bleeding gastric ulcer causing gastric wall necrosis: A case report
Li WF, Gao RY, Xu JW, Yu XQ
- 1208** Intermittent melena and refractory anemia due to jejunal cavernous lymphangioma: A case report
Liu KR, Zhang S, Chen WR, Huang YX, Li XG

LETTER TO THE EDITOR

- 1215** New frontiers in ectopic pancreatic tissue management
Covantsev S

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Surgery*, Arunachalam Rathnaswami, FACS, MBBS, MS, MNAMS, MCh, Ex-Professor and Head, Department of Surgical Gastroenterology, SRM Medical College Hospital and Research Institute SRMIST, Kattankulathur, Chennai, TamilNadu 603203, India. arunarathna@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Surgery* (WJGS, *World J Gastrointest Surg*) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, *etc.*

INDEXING/ABSTRACTING

The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGS as 2.0; IF without journal self cites: 1.9; 5-year IF: 2.2; Journal Citation Indicator: 0.52; Ranking: 113 among 212 journals in surgery; Quartile category: Q3; Ranking: 81 among 93 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Zi-Hang Xu, Production Department Director: Xiang Li, Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastrointestinal Surgery

ISSN

ISSN 1948-9366 (online)

LAUNCH DATE

November 30, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Peter Schemmer

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-9366/editorialboard.htm>

PUBLICATION DATE

April 27, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Relationship between *Helicobacter pylori* infection and colorectal polyp/colorectal cancer

Ying Liu, Ding-Quan Yang, Jun-Nan Jiang, Yan Jiao

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Bordin DS, Russia; Cassell III AK, Liberia

Received: January 10, 2024

Peer-review started: January 10, 2024

First decision: January 27, 2024

Revised: February 1, 2024

Accepted: March 13, 2024

Article in press: March 13, 2024

Published online: April 27, 2024



Ying Liu, Department of General Surgery, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun 130021, Jilin Province, China

Ding-Quan Yang, Jun-Nan Jiang, Department of Gastrointestinal and Colorectal Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China

Yan Jiao, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China

Corresponding author: Yan Jiao, MD, PhD, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com

Abstract

Helicobacter pylori (*H. pylori*) plays an important role in the development of gastric cancer, although its association to colorectal polyp (CP) or colorectal cancer (CRC) is unknown. In this issue of *World Journal of Gastrointestinal Surgery*, Zhang *et al* investigated the risk factors for *H. pylori* infection after colon polyp resection. Importantly, the researchers used R software to create a prediction model for *H. pylori* infection based on their findings. This editorial gives an overview of the association between *H. pylori* and CP/CRC, including the clinical significance of *H. pylori* as an independent risk factor for CP/CRC, the underlying processes of *H. pylori*-associated carcinogenesis, and the possible risk factors and identification of *H. pylori*.

Key Words: *Helicobacter pylori*; Colorectal polyp; Colorectal cancer; Risk factor

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: *Helicobacter pylori* (*H. pylori*) infection is a significant risk factor for colorectal adenomatous polyp (CAP) or colorectal cancer (CRC), and it may contribute to the development of CRC via an inflammatory response, gastrin stimulation, intestinal flora modulation, and virulence factor invasion. In contrast, the diagnosis of CAP may independently predict the probability of *H. pylori* infection after colon polyp removal.

Citation: Liu Y, Yang DQ, Jiang JN, Jiao Y. Relationship between *Helicobacter pylori* infection and colorectal polyp/colorectal cancer. *World J Gastrointest Surg* 2024; 16(4): 1008-1016

URL: <https://www.wjgnet.com/1948-9366/full/v16/i4/1008.htm>

DOI: <https://dx.doi.org/10.4240/wjgs.v16.i4.1008>

INTRODUCTION

Helicobacter pylori (*H. pylori*) is a microaerophilic, gram-negative bacteria that lives mostly in the stomach and duodenum of humans. It spreads to individuals by a variety of routes, including oral-oral, fecal-oral, and gastro-oral pathways[1]. Because to *H. pylori*'s various transmission channels, growing medication resistance, poor eradication rate, and insufficient treatment duration, 43.1 percent of the world population was infected from 2011 to 2022[2]. In impoverished nations, the *H. pylori* infection rate approached 70%, while infection rates in affluent countries varied from 25% to 50%[3]. Although most people with *H. pylori* infection are asymptomatic, long-term infection may cause chronic gastritis and is linked to a variety of non-gastric ailments, including atherosclerosis[4], type 2 diabetes[5], anemia[6], osteoporosis[7], and some immune-related disorders[8]. Furthermore, 1%-3% of those infected with *H. pylori* develop gastric cancer[9], and *H. pylori* infection is also strongly related with mucosa-associated lymphoid tissue lymphoma[10] and colorectal cancer (CRC)[11]. As a result, the World Health Organization's International Cancer Research Centre designated *H. pylori* as a Class I biological carcinogen[12]. In conclusion, screening and eradication of *H. pylori* is an important primary preventative method for tumorigenesis[13].

In recent decades, the connection between *H. pylori* and colorectal polyp (CP) or CRC has sparked attention. And, there is accumulating clinical and basic experiment evidence indicating that *H. pylori* infection is a risk factor for CP/CRC and promotes the development of CRC. In this paper, two researchers (DQ-Y and Y-L) conducted independent literature searches using PubMed, Embase, and Cochrane Library databases to obtain more comprehensive literature data. The search was conducted from inception to December 2023, with search keywords including "*Helicobacter pylori*", "*H. pylori*", "*Helicobacter pylori* infection", "*H. pylori* infection", "colorectal polyp", "CP", "colorectal adenomatous polyp", "CAP", "colorectal adenoma", "colorectal neoplasm", "colorectal neoplasia", "colorectal cancer", "colorectal carcinoma", "CRC", and "colorectal tumor". Additionally, manual searches of the reference lists of the obtained articles were conducted to avoid any omission of studies. Further, we investigate the link between *H. pylori* and CP/CRC, as well as the possible pathogenic processes involved.

THE ASSOCIATION BETWEEN *H. PYLORI* AND CP/CRC

Several case-control and retrospective cohort studies have shown a substantial link between *H. pylori* infection and the prevalence of CP/CRC[14-17]. Similarly, cross-sectional studies conducted in various areas and nations consistently shown that *H. pylori* infection was an independent risk factor for CP, especially colorectal adenomatous polyp (CAP)[18-21]. Boustany et al[22] reported the first findings from a large population-based analysis of 47714750 people, establishing an independent link between a history of *H. pylori* infection and the risk of CRC. A large-scale meta-analysis of 48 studies found that both CAP and CRC were linked to *H. pylori* infection[23]. Yang et al[24] used a fixed-effects model to analyze 27 studies and discovered that different study methods, including case-control studies [odds ratio (OR) = 1.26, 95% confidence interval (95%CI): 1.16-1.36], cross-sectional studies (OR = 1.92, 95%CI: 1.17-3.16), and multiple detection methods (OR = 2.63, 95%CI: 1.09-6.31), all supported the strong link between *H. pylori* infection and an increased risk of CRC. A prospective European multi-center investigation found that serum antibodies to *H. pylori* protein C and cytotoxin-associated gene A were linked to an elevated risk of CRC[25]. *H. pylori* infection in patients with atrophic gastritis [26], intestinal metaplasia[27], diabetes[28], and metabolic syndrome[29] may enhance the risk of CAP. Further-more, as demonstrated in Table 1, *H. pylori* infection is linked to pathological clinical characteristics such as the size, number, location, and pathological type of CAP.

Individuals with present or past *H. pylori* infection have a 30% to 50% higher risk of developing CRC[30]. *H. pylori* infection was discovered as a predictive factor for the construction of the CAP-risk model, which has shown excellent clinical relevance in prospective cohort studies[31]. Triple treatment coupled with long-term use of proton pump inhibitors may lower the incidence of CAP caused by *H. pylori* infection[32], and *H. pylori* eradication before to surgery may become a novel immunotherapy method for CRC[33]. In contrast, if *H. pylori* is not adequately treated and continues, it might considerably increase the recurrence risk of CAP[34-36].

However, several clinical research did not find a substantial link between *H. pylori* and CP/CRC[37-39]. We take into account the criteria for positive *H. pylori* infection, *H. pylori* diagnostic methods, the interference of *H. pylori*-related diseases[26], incomplete colonoscopy, sample size and age[40,41], as well as ethnic[30,41] and regional environmental differences, all of which may lead to inconsistent results.

Zhang et al[42] performed thorough scientific research in this issue of *World Journal of Gastrointestinal Surgery* and proposed a novel route for researching the association between *H. pylori* and CP. The research found that age, body mass index (BMI), and CAP were independent predictors of *H. pylori* infection after post-colon polyp resection. In addition, the research used R software to create a column-line graph prediction model. The model has been demonstrated to have strong calibration, discrimination, and prediction abilities in predicting *H. pylori* risk by calculating calibration curves,

Table 1 The correlation between *Helicobacter pylori* infection and the clinicopathologic characteristics of colorectal polyp

Characteristics	Variables related to <i>H. pylori</i> infection		Ref.
	Variable	Correlation with <i>H. pylori</i> infection	
Polyp size (diameter)	> 1.0 cm	Positive	[14,93,95,96]
Polyp/adenomatous polyp number	> 1.0	Negative	[93]
		Positive	[17,95-99]
Pathological type	Adenoma (all)	Positive	[19-21,23,26,27,35,97,98,100-106]
	Tubular adenoma	Positive	[34,107]
	Villous adenoma	Positive	[14,93,96,107]
	Tubular villous adenoma	Positive	[14,34]
	Hyperplastic polyp	Positive	[36,96,103]
	Serrated polyp	Positive	[108]
Adenomatous polyp stage	Advanced adenoma	Positive	[17,23,93,96,103,105]
Distribution of adenomatous polyp	Proximal	Positive	[17,19]

H. pylori: *Helicobacter pylori*.

receiver operating characteristic curves, and decision curve analysis curves, as well as validating the model validation cohort. This prediction approach might aid in the early detection of *H. pylori* infection.

POTENTIAL CARCINOGENIC EFFECT OF *H. PYLORI* ON CRC

Impact of *H. pylori*-related inflammation on CRC

H. pylori is a major immunostimulant. Ralser *et al*[11] discovered that in the Apc mutant mouse model, *H. pylori* infection recruited CD3+ T cells within the colon tissue epithelium, upregulated CD8+ T cells, and caused Treg cell loss and differentiation into potentially pathogenic Foxp3+ IL-17A+ T cells[43], resulting in a specific pro-inflammatory immune response. Furthermore, the research found that *H. pylori* might activate the STAT3 cancer pathway in colon cells, further blocking Treg cell infiltration[44], which was followed by elevated Ki67 expression and reduced intestinal barrier marker PAS[11]. This research also provides the first direct evidence of a causal link between *H. pylori* infection and CRC. Furthermore, *H. pylori* may produce chronic gastritis, which exacerbates the systemic inflammatory response[45]. Inflammation has been linked to an increased risk of CRC, and long-term usage of aspirin as an anti-inflammatory medication may help prevent CRC[46]. Future research in CRC will concentrate on the inflammatory stimulation and immunological modulation related with *H. pylori* infection.

Gastrin and CRC

Gastric atrophy produced by *H. pylori*-related gastritis results in hypergastrinemia following hypochlorhydria[47], and serum gastrin and *H. pylori* IgG are linked with an increased risk of CRC[48]. As a result, more research has focused on the relationship between gastrin and CRC, and it has been discovered that cholecystokinin B/gastrin receptors are over-expressed in CAP and CRC[49], and the gastrin binding capacity of CRC is ten times greater than that of normal colonic mucosa, promoting cell growth[50,51]. Furthermore, gastrin and progastrin have been shown to be released by CRC cells [52], and they operate as autocrine/paracrine growth factors to stimulate growth/anti-apoptosis in normal colonic mucosal cells, influencing gland development and shape[53,54]. Surprisingly, certain CRC cell proliferation may rely more on autocrine progastrin[55].

The role of gastrin in facilitating the advancement of the adenoma-carcinoma sequence in the colorectum has also received attention. Autocrine progastrin may activate Src kinase in CRC cells, hence mediating the proliferation/anti-apoptotic actions of endocrine/autocrine progastrin[56-58]. Furthermore, *in vitro* and *in vivo* research have revealed that the progastrin-related pathway may disturb normal stem cell populations by upregulating CD133, CD44, DCLK1, and Lgr5 stem cell markers, increasing cancer cells' oncogenic and metastatic potential[56,59-61]. Progastrin also binds to the G protein-coupled receptor 56 in colon stem cells, conferring growth potential[62]. Furthermore, gastrin has been shown to upregulate many colon cancer target genes, including cyclin D1, vascular endothelial growth factor, vascular endothelial-cadherin, and matrix metalloproteinase-2, promoting tumor development[63-65]. Although different data point to the oncogenic qualities of gastrin and its derivatives, further study is required to determine the particular involvement of gastrin in the development of CRC.

Changes in intestinal flora associated with *H. pylori* infection

Environmental variables, such as food structure and intestinal flora, account for 80%-85% of CRC, and changes in intestinal microbial balance may function as environmental triggers for CRC[66]. The quantity of intestinal flora varies with the origin and evolution of CRC[67]. Simultaneously, increased abundance of pro-tumor bacteria such as polyketide synthase-positive (pks+) *Escherichia coli* (*E. coli*), enterotoxigenic *Bacteroides fragilis*, and *Fusobacterium nucleatum* can promote intestinal inflammation *via* toxins or metabolites, facilitate tumor cell proliferation and migration, and create an immunosuppressive microenvironment that limits anti-tumor immunity[68,69]. The preceding data indicate that the intestinal flora plays an important role in the development of CRC and influences tumor chemotherapy and immunotherapy[70].

Chronic *H. pylori* infection is a major cause of diminished microbial diversity in the stomach[71]. It also boosts the number of microorganisms in stomach cancer, including nitrate-reducing bacteria, nitrosylbacteria, and *E. coli*, which promotes nitrate metabolism. The resultant N-nitroso compounds function as carcinogens and promote tumorigenesis[72]. An increasing body of evidence suggests that *H. pylori* infection also impacts the intestinal flora. *H. pylori* invasion of the intestinal mucosa may lead to reduced intestinal permeability[72] and inhibit *E. coli* DNA[73]. *H. pylori* may also trigger host immune responses, thereby altering the intestinal flora[74,75]. Furthermore, long-term *H. pylori* infection can alter the pH in the stomach, enabling more microorganisms to overcome the acid barrier and enter the distal intestinal tract[75]. CagA also can stimulate the overproliferation of intestinal stem cells and alter the host microbiota[76]. Recent study has revealed that *H. pylori* promotes the enrichment of *Akkermansia* spp. and *Ruminococcus* spp., which breakdown intestinal mucus, in the colon tissue of *H. pylori*-infected mice, resulting in a pro-inflammatory and pro-carcinogenic microbiota signature[11]. It is possible that *H. pylori* infection weakens the intestinal barrier. Furthermore, Luo *et al*[77] discovered that in the early stages of CRC development, *H. pylori* infection promotes the amplification of temperate phages to disrupt intestinal virome homeostasis and interacts with bacterial communities to target tumor-associated bacteria such as *Lactobacillus*[78] and *Enterococcus faecalis*[79], promoting the development of CRC in mice. To summarize, *H. pylori*-induced intestinal flora dysbiosis is a significant risk factor for the development of CRC.

The virulence factors of *H. pylori*

H. pylori's virulence components, including as CagA, vacuolating cytotoxin A (VacA), and high-temperature requirement A, play a crucial role in the process by which *H. pylori* causes stomach cancer. These virulence factors may increase the onset and development of gastric cancer by altering cell structure and shape, as well as impairing cell proliferation and apoptosis[80]. Some investigations have shown that CagA expression[81-83] and the serological response to *H. pylori* VacA, particularly in African Americans[30], are related with an elevated risk of CRC formation. Furthermore, infection with robust strains of CagA-positive *H. pylori* may contribute to the development of CRC by eliciting increased inflammatory responses[84]. There is some indication that *H. pylori* may be present in CPs[85,86], however further data is required to show the direct influence of *H. pylori* bacterial components on the development of CRC. It cannot be ruled out that virulence factors like VacA may easily spread outside the stomach wall[30,87], thereby causing cancer.

RISK FACTORS FOR *H. PYLORI* INFECTION

A variety of variables impact *H. pylori* infection rates, including economic position, living circumstances, cleanliness, lifestyle, occupation, and drinking water quality[88]. It is also difficult for *H. pylori* infections to resolve spontaneously[89]. According to current research, *H. pylori* infection rates are increased in obesity[90], portal hypertensive gastropathy[91], periodontal disease[92], and colon polyps[93]. In addition, untreated dental caries may have an impact on systemic *H. pylori* infection[94]. Zhang *et al*[42] hypothesized that age, BMI, and CAP were risk factors for *H. pylori* infection after post-colon polyp surgery. Perhaps particular disorders can be utilized to identify those who are at high risk for *H. pylori* infection.

CONCLUSION

In conclusion, Zhang *et al*[42] performed a retrospective clinical study and discovered that age, BMI, and CAP were independent predictors of *H. pylori* infection after postcolon polyp surgery. They also created a column-line graph prediction model with high calibration and predictive power for predicting the probability of *H. pylori* infection. However, the *H. pylori* prediction model may still be improved. Future studies should control for major confounding variables such as age, metabolic parameters, smoking, alcohol intake, physical activity, food, racial variations, socioeconomic level, and antibiotic usage. The investigation should also look into the association between the period of *H. pylori* infection or recurrence following post-colon polyp surgery and CAP. Simultaneously, multi-center, large-scale prospective research should be carried out to create a scientifically rigorous *H. pylori*-CRC screening program. More emphasis should be placed on the simultaneous diagnosis of CAP and *H. pylori*-related disorders[4-8,92,94] or specific diseases[91]. This technique will not only increase the screening rate of those at high risk of *H. pylori* infection and the diagnostic rate of infected individuals, but will also allow for a better understanding of the mechanism behind the link between *H. pylori* infection and the development of CRC.

FOOTNOTES

Author contributions: Liu Y contributed to the writing, editing of the manuscript and table, and literature search; Yang DQ contributed to the discussion, design of the manuscript and literature search; Jiang JN contributed to the discussion and design of the manuscript; and Jiao Y designed the overall concept and outline of the manuscript.

Supported by the Health Science and Technology Capacity Improvement Project of Health Commission of Jilin Provincial, No. 2023JC016.

Conflict-of-interest statement: The authors have claimed no conflict of interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Yan Jiao 0000-0001-6914-7949.

S-Editor: Chen YL

L-Editor: A

P-Editor: Xu ZH

REFERENCES

- Sun Q, Yuan C, Zhou S, Lu J, Zeng M, Cai X, Song H. Helicobacter pylori infection: a dynamic process from diagnosis to treatment. *Front Cell Infect Microbiol* 2023; **13**: 1257817 [PMID: 37928189 DOI: 10.3389/fcimb.2023.1257817]
- Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2023; **8**: 553-564 [PMID: 37086739 DOI: 10.1016/S2468-1253(23)00070-5]
- Alipour M. Molecular Mechanism of Helicobacter pylori-Induced Gastric Cancer. *J Gastrointest Cancer* 2021; **52**: 23-30 [PMID: 32926335 DOI: 10.1007/s12029-020-00518-5]
- Riad M. Association of Helicobacter pylori infection with coronary artery disease: is it an independent risk factor? *Egypt Heart J* 2021; **73**: 61 [PMID: 34216301 DOI: 10.1186/s43044-021-00185-2]
- Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. *Front Immunol* 2020; **11**: 1582 [PMID: 32793223 DOI: 10.3389/fimmu.2020.01582]
- Hou B, Zhang M, Liu M, Dai W, Lin Y, Li Y, Gong M, Wang G. Association of active Helicobacter pylori infection and anemia in elderly males. *BMC Infect Dis* 2019; **19**: 228 [PMID: 30836932 DOI: 10.1186/s12879-019-3849-y]
- Fisher L, Fisher A, Smith PN. Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review). *J Clin Med* 2020; **9** [PMID: 33053671 DOI: 10.3390/jcm9103253]
- Wang L, Cao ZM, Zhang LL, Dai XC, Liu ZJ, Zeng YX, Li XY, Wu QJ, Lv WL. Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems. *Front Immunol* 2022; **13**: 833424 [PMID: 35222423 DOI: 10.3389/fimmu.2022.833424]
- Butt J, Epplein M. Helicobacter pylori and colorectal cancer-A bacterium going abroad? *PLoS Pathog* 2019; **15**: e1007861 [PMID: 31393968 DOI: 10.1371/journal.ppat.1007861]
- Chang WL, Yeh YC, Sheu BS. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. *J Biomed Sci* 2018; **25**: 68 [PMID: 30205817 DOI: 10.1186/s12929-018-0466-9]
- Ralser A, Dietl A, Jarosch S, Engelsberger V, Wanisch A, Janssen KP, Middelhoff M, Vieth M, Quante M, Haller D, Busch DH, Deng L, Mejias-Luque R, Gerhard M. Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature. *Gut* 2023; **72**: 1258-1270 [PMID: 37015754 DOI: 10.1136/gutjnl-2022-328075]
- Crowe SE. Helicobacter pylori Infection. *N Engl J Med* 2019; **380**: 1158-1165 [PMID: 30893536 DOI: 10.1056/NEJMcp1710945]
- Kamboj AK, Cotter TG, Oxentenko AS. Helicobacter pylori: The Past, Present, and Future in Management. *Mayo Clin Proc* 2017; **92**: 599-604 [PMID: 28209367 DOI: 10.1016/j.mayocp.2016.11.017]
- Basmaci N, Karataş A, Ergin M, Dumlu GŞ. Association between Helicobacter pylori infection and colorectal polyps. *Medicine (Baltimore)* 2023; **102**: e35591 [PMID: 37861565 DOI: 10.1097/MD.00000000000035591]
- Liu IL, Tsai CH, Hsu CH, Hu JM, Chen YC, Tian YF, You SL, Chen CY, Hsiao CW, Lin CY, Chou YC, Sun CA. Helicobacter pylori infection and the risk of colorectal cancer: a nationwide population-based cohort study. *QJM* 2019; **112**: 787-792 [PMID: 31250012 DOI: 10.1093/qjmed/hcz157]
- Zhang Y, Hoffmeister M, Weck MN, Chang-Claude J, Brenner H. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. *Am J Epidemiol* 2012; **175**: 441-450 [PMID: 22294430 DOI: 10.1093/aje/kwr331]
- Nam JH, Hong CW, Kim BC, Shin A, Ryu KH, Park BJ, Kim B, Sohn DK, Han KS, Kim J, Lee CW. Helicobacter pylori infection is an independent risk factor for colonic adenomatous neoplasms. *Cancer Causes Control* 2017; **28**: 107-115 [PMID: 28025763 DOI: 10.1007/s10552-016-0839-x]
- Feng L, Zhao K, Wang G, Dong R, Zhang M, Xia S, Zhang Y, Zhou W, Tian D, Yan W, Liao J. Relationship between endoscopic gastric abnormalities and colorectal polyps: a cross-sectional study based on 33439 Chinese patients. *Int J Med Sci* 2023; **20**: 219-224 [PMID: 36794160 DOI: 10.7150/ijms.80543]

- 19 Kim TJ, Kim ER, Chang DK, Kim YH, Baek SY, Kim K, Hong SN. Helicobacter pylori infection is an independent risk factor of early and advanced colorectal neoplasm. *Helicobacter* 2017; **22** [PMID: 28124492 DOI: 10.1111/hel.12377]
- 20 Shen L, Bian R, Wang W, Zhao J. Association of Helicobacter pylori infection with colorectal adenoma in the Chinese urban population: A cross-sectional study. *Microb Pathog* 2021; **158**: 105111 [PMID: 34324998 DOI: 10.1016/j.micpath.2021.105111]
- 21 Tongtawee T, Simawaranon T, Wattanawongdon W. Role of screening colonoscopy for colorectal tumors in Helicobacter pylori-related chronic gastritis with MDM2 SNP309 G/G homozygous: A prospective cross-sectional study in Thailand. *Turk J Gastroenterol* 2018; **29**: 555-560 [PMID: 30260777 DOI: 10.5152/tjg.2018.17608]
- 22 Boustany A, Onwuzo S, Almomani A, Asaad I. Epidemiology and risk of colorectal cancer in patients with a history of Helicobacter pylori infection: a population-based study. *Ann Gastroenterol* 2023; **36**: 203-207 [PMID: 36864940 DOI: 10.20524/aog.2023.0783]
- 23 Choi DS, Seo SI, Shin WG, Park CH. Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis. *Clin Transl Gastroenterol* 2020; **11**: e00127 [PMID: 32032128 DOI: 10.14309/ctg.000000000000127]
- 24 Yang F, Xu YL, Zhu RF. Helicobacter pylori infection and the risk of colorectal carcinoma: a systematic review and meta-analysis. *Minerva Med* 2019; **110**: 464-470 [PMID: 31368293 DOI: 10.23736/S0026-4806.19.05942-1]
- 25 Butt J, Jenab M, Pawlita M, Tjønneland A, Kyrø C, Boutron-Ruault MC, Carbonnel F, Dong C, Kaaks R, Kühn T, Boeing H, Schulze MB, Trichopoulou A, Karakatsani A, La Vecchia C, Palli D, Agnoli C, Tumino R, Sacerdote C, Panico S, Bueno-de-Mesquita B, Vermeulen R, Gram IT, Weiderpass E, Borch KB, Quirós JR, Agudo A, Rodríguez-Barranco M, Santiuste C, Ardanaz E, Van Guelpen B, Harlid S, Imaz L, Perez-Cornago A, Gunter MJ, Zouiouich S, Park JY, Riboli E, Cross AJ, Heath AK, Waterboer T, Hughes DJ. Antibody Responses to Helicobacter pylori and Risk of Developing Colorectal Cancer in a European Cohort. *Cancer Epidemiol Biomarkers Prev* 2020; **29**: 1475-1481 [PMID: 32332031 DOI: 10.1158/1055-9965.EPI-19-1545]
- 26 Chen QF, Zhou XD, Fang DH, Zhang EG, Lin CJ, Feng XZ, Wang N, Wu JS, Wang D, Lin WH. Helicobacter pylori infection with atrophic gastritis: An independent risk factor for colorectal adenomas. *World J Gastroenterol* 2020; **26**: 5682-5692 [PMID: 33088161 DOI: 10.3748/wjg.v26.i37.5682]
- 27 Yan Y, Chen YN, Zhao Q, Chen C, Lin CJ, Jin Y, Pan S, Wu JS. Helicobacter pylori infection with intestinal metaplasia: An independent risk factor for colorectal adenomas. *World J Gastroenterol* 2017; **23**: 1443-1449 [PMID: 28293091 DOI: 10.3748/wjg.v23.i8.1443]
- 28 Ko HJ, Lin YC, Chen CC, Chen MJ, Wu MS, Liu CJ, Huang CT, Yang HW, Shih SC, Yu LY, Kuo YC, Wang HY, Hu KC. Helicobacter pylori infection and increased diabetes prevalence were the risks of colorectal adenoma for adults: A systematic review and meta-analysis (PRISMA-compliant article). *Medicine (Baltimore)* 2021; **100**: e28156 [PMID: 34918670 DOI: 10.1097/MD.00000000000028156]
- 29 Lin YL, Chiang JK, Lin SM, Tseng CE. Helicobacter pylori infection concomitant with metabolic syndrome further increase risk of colorectal adenomas. *World J Gastroenterol* 2010; **16**: 3841-3846 [PMID: 20698048 DOI: 10.3748/wjg.v16.i30.3841]
- 30 Butt J, Varga MG, Blot WJ, Teras L, Visvanathan K, Le Marchand L, Haiman C, Chen Y, Bao Y, Sesso HD, Wassertheil-Smoller S, Ho GYF, Tinker LE, Peek RM, Potter JD, Cover TL, Hendrix LH, Huang LC, Hyslop T, Um C, Grodstein F, Song M, Zeleniuch-Jacquotte A, Berndt S, Hildesheim A, Waterboer T, Pawlita M, Epplein M. Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States. *Gastroenterology* 2019; **156**: 175-186.e2 [PMID: 30296434 DOI: 10.1053/j.gastro.2018.09.054]
- 31 Li W, Chen Z, Chen H, Han X, Zhang G, Zhou X. Establish a Novel Model for Predicting the Risk of Colorectal Adenomatous Polyps: a Prospective Cohort Study. *J Cancer* 2022; **13**: 3103-3112 [PMID: 36046645 DOI: 10.7150/jca.74772]
- 32 Zuniga R, Bautista J, Sapra K, Westerfield K, Williams S, Sy AM. Combination of Triple Therapy and Chronic PPI Use May Decrease Risk of Colonic Adenomatous Polyps in Helicobacter pylori Infection. *Gastroenterol Res Pract* 2015; **2015**: 638547 [PMID: 26064095 DOI: 10.1155/2015/638547]
- 33 Urakawa S, Yamasaki M, Makino T, Kurokawa Y, Yamamoto K, Goto K, Haruna M, Hirata M, Morimoto-Okazawa A, Kawashima A, Iwahori K, Mizushima T, Sato E, Mori M, Doki Y, Wada H. The impact of ICOS(+) regulatory T cells and Helicobacter pylori infection on the prognosis of patients with gastric and colorectal cancer: potential prognostic benefit of pre-operative eradication therapy. *Cancer Immunol Immunother* 2021; **70**: 443-452 [PMID: 32803278 DOI: 10.1007/s00262-020-02696-4]
- 34 Kang KH, Hwang SH, Kim D, Kim DH, Kim SY, Hyun JJ, Jung SW, Koo JS, Jung YK, Yim HJ, Lee SW. [The Effect of Helicobacter pylori Infection on Recurrence of Gastric Hyperplastic Polyp after Endoscopic Removal]. *Korean J Gastroenterol* 2018; **71**: 213-218 [PMID: 29684970 DOI: 10.4166/kjg.2018.71.4.213]
- 35 Hu KC, Wu MS, Chu CH, Wang HY, Lin SC, Liu CC, Su TH, Liao WC, Chen CL, Liu CJ, Shih SC. Decreased Colorectal Adenoma Risk After Helicobacter pylori Eradication: A Retrospective Cohort Study. *Clin Infect Dis* 2019; **68**: 2105-2113 [PMID: 30566695 DOI: 10.1093/cid/ciy591]
- 36 Cho YS, Nam SY, Moon HS, Kim TH, Kim SE, Jung JT. Helicobacter pylori eradication reduces risk for recurrence of gastric hyperplastic polyp after endoscopic resection. *Korean J Intern Med* 2023; **38**: 167-175 [PMID: 36437035 DOI: 10.3904/kjim.2022.111]
- 37 Luo F, Zhou P, Ran X, Gu M, Zhou S. No evident causal association between Helicobacter pylori infection and colorectal cancer: a bidirectional mendelian randomization study. *Sci Rep* 2023; **13**: 18544 [PMID: 37899462 DOI: 10.1038/s41598-023-45545-x]
- 38 Fernández de Larrea-Baz N, Michel A, Romero B, Pérez-Gómez B, Moreno V, Martín V, Dierssen-Sotos T, Jiménez-Moleón JJ, Castilla J, Tardón A, Ruiz I, Peiró R, Tejada A, Chirlaque MD, Butt JA, Olmedo-Requena R, Gómez-Acebo I, Linares P, Boldo E, Castells A, Pawlita M, Castaño-Vinyals G, Kogevinas M, de Sanjosé S, Pollán M, Del Campo R, Waterboer T, Aragonés N. Helicobacter pylori Antibody Reactivities and Colorectal Cancer Risk in a Case-control Study in Spain. *Front Microbiol* 2017; **8**: 888 [PMID: 28611733 DOI: 10.3389/fmicb.2017.00888]
- 39 Grahm N, Hmani-Aifa M, Fransén K, Söderkvist P, Monstein HJ. Molecular identification of Helicobacter DNA present in human colorectal adenocarcinomas by 16S rDNA PCR amplification and pyrosequencing analysis. *J Med Microbiol* 2005; **54**: 1031-1035 [PMID: 16192433 DOI: 10.1099/jmm.0.46122-0]
- 40 Luan C, Liu Z, Li Y, Dong T. Association among helicobacter pylori infection, gastrin level and colorectal cancer in patients aged 50 years and over. *Pak J Med Sci* 2020; **36**: 899-903 [PMID: 32704260 DOI: 10.12669/pjms.36.5.1993]
- 41 Blase JL, Campbell PT, Gapstur SM, Pawlita M, Michel A, Waterboer T, Teras LR. Prediagnostic Helicobacter pylori Antibodies and Colorectal Cancer Risk in an Elderly, Caucasian Population. *Helicobacter* 2016; **21**: 488-492 [PMID: 27006167 DOI: 10.1111/hel.12305]
- 42 Zhang ZS. Predictive factors and model validation of post-colon polyp surgery Helicobacter pylori infection. *World J Gastrointest Surg* 2024; **16**: 173-185 [PMID: 38328335 DOI: 10.4240/wjgs.v16.i1.173]
- 43 Yang S, Wang B, Guan C, Wu B, Cai C, Wang M, Zhang B, Liu T, Yang P. Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer. *J Leukoc Biol* 2011; **89**: 85-91 [PMID: 20952660 DOI: 10.1189/jlb.0910506]

- 44 **Nguyen AV**, Wu YY, Liu Q, Wang D, Nguyen S, Loh R, Pang J, Friedman K, Orlofsky A, Augenlicht L, Pollard JW, Lin EY. STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon. *Neoplasia* 2013; **15**: 998-1008 [PMID: 24027425 DOI: 10.1593/neo.13952]
- 45 **Jackson L**, Britton J, Lewis SA, McKeever TM, Atherton J, Fullerton D, Fogarty AW. A population-based epidemiologic study of *Helicobacter pylori* infection and its association with systemic inflammation. *Helicobacter* 2009; **14**: 108-113 [PMID: 19751435 DOI: 10.1111/j.1523-5378.2009.00711.x]
- 46 **Brenner H**, Kloor M, Pox CP. Colorectal cancer. *Lancet* 2014; **383**: 1490-1502 [PMID: 24225001 DOI: 10.1016/S0140-6736(13)61649-9]
- 47 **Duan S**, Rico K, Merchant JL. Gastrin: From Physiology to Gastrointestinal Malignancies. *Function (Oxf)* 2022; **3**: zqab062 [PMID: 35330921 DOI: 10.1093/function/zqab062]
- 48 **Zhang QY**, Lv Z, Sun LP, Dong NN, Xing CZ, Yuan Y. Clinical significance of serum markers reflecting gastric function and *H. pylori* infection in colorectal cancer. *J Cancer* 2019; **10**: 2229-2236 [PMID: 31258726 DOI: 10.7150/jca.27134]
- 49 **Smith AM**, Watson SA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. *Gut* 2000; **47**: 820-824 [PMID: 11076881 DOI: 10.1136/gut.47.6.820]
- 50 **Smith JP**, Stock EA, Wotring MG, McLaughlin PJ, Zagon IS. Characterization of the CCK-B/gastrin-like receptor in human colon cancer. *Am J Physiol* 1996; **271**: R797-R805 [PMID: 8853405 DOI: 10.1152/ajpregu.1996.271.3.R797]
- 51 **Zeng Q**, Ou L, Wang W, Guo DY. Gastrin, Cholecystokinin, Signaling, and Biological Activities in Cellular Processes. *Front Endocrinol (Lausanne)* 2020; **11**: 112 [PMID: 32210918 DOI: 10.3389/fendo.2020.00112]
- 52 **Singh P**, Dai B, Wu H, Owlia A. Role of autocrine and endocrine gastrin-like peptides in colonic carcinogenesis. *Curr Opin Gastroenterol* 2000; **16**: 68-77 [PMID: 17024020 DOI: 10.1097/00001574-200001000-00013]
- 53 **Rengifo-Cam W**, Singh P. Role of progastrins and gastrins and their receptors in GI and pancreatic cancers: targets for treatment. *Curr Pharm Des* 2004; **10**: 2345-2358 [PMID: 15279613 DOI: 10.2174/1381612043383999]
- 54 **Ramanathan V**, Jin G, Westphalen CB, Whelan A, Dubeykovskiy A, Takaishi S, Wang TC. P53 gene mutation increases progastrin dependent colonic proliferation and colon cancer formation in mice. *Cancer Invest* 2012; **30**: 275-286 [PMID: 22480191 DOI: 10.3109/07357907.2012.657814]
- 55 **Singh P**, Owlia A, Varro A, Dai B, Rajaraman S, Wood T. Gastrin gene expression is required for the proliferation and tumorigenicity of human colon cancer cells. *Cancer Res* 1996; **56**: 4111-4115 [PMID: 8797575]
- 56 **Singh P**, Sarkar S, Kantara C, Maxwell C. Progastrin Peptides Increase the Risk of Developing Colonic Tumors: Impact on Colonic Stem Cells. *Curr Colorectal Cancer Rep* 2012; **8**: 277-289 [PMID: 23226720 DOI: 10.1007/s11888-012-0144-3]
- 57 **Kovac S**, Shulkes A, Baldwin GS. Peptide processing and biology in human disease. *Curr Opin Endocrinol Diabetes Obes* 2009; **16**: 79-85 [PMID: 19104240 DOI: 10.1097/MED.0b013e3283202555]
- 58 **Belli S**, Esposito D, Servetto A, Pesapane A, Formisano L, Bianco R. c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve? *Cancers (Basel)* 2020; **12** [PMID: 32517369 DOI: 10.3390/cancers12061489]
- 59 **Sarkar S**, Kantara C, Ortiz I, Swiercz R, Kuo J, Davey R, Escobar K, Ullrich R, Singh P. Progastrin overexpression imparts tumorigenic/metastatic potential to embryonic epithelial cells: phenotypic differences between transformed and nontransformed stem cells. *Int J Cancer* 2012; **131**: E1088-E1099 [PMID: 22532325 DOI: 10.1002/ijc.27615]
- 60 **Ferrand A**, Sandrin MS, Shulkes A, Baldwin GS. Expression of gastrin precursors by CD133-positive colorectal cancer cells is crucial for tumour growth. *Biochim Biophys Acta* 2009; **1793**: 477-488 [PMID: 19321126 DOI: 10.1016/j.bbamcr.2009.01.004]
- 61 **Sarkar S**, Swiercz R, Kantara C, Hajjar KA, Singh P. Annexin A2 mediates up-regulation of NF- κ B, β -catenin, and stem cell in response to progastrin in mice and HEK-293 cells. *Gastroenterology* 2011; **140**: 583-595.e4 [PMID: 20826156 DOI: 10.1053/j.gastro.2010.08.054]
- 62 **Jin G**, Sakitani K, Wang H, Jin Y, Dubeykovskiy A, Worthley DL, Tailor Y, Wang TC. The G-protein coupled receptor 56, expressed in colonic stem and cancer cells, binds progastrin to promote proliferation and carcinogenesis. *Oncotarget* 2017; **8**: 40606-40619 [PMID: 28380450 DOI: 10.18632/oncotarget.16506]
- 63 **Ferrand A**, Wang TC. Gastrin and cancer: a review. *Cancer Lett* 2006; **238**: 15-29 [PMID: 16054292 DOI: 10.1016/j.canlet.2005.06.025]
- 64 **Najib S**, Kowalski-Chauvel A, Do C, Roche S, Cohen-Jonathan-Moyal E, Seva C. Progastrin a new pro-angiogenic factor in colorectal cancer. *Oncogene* 2015; **34**: 3120-3130 [PMID: 25109333 DOI: 10.1038/onc.2014.255]
- 65 **Clarke PA**, Dickson JH, Harris JC, Grabowska A, Watson SA. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. *Cancer Res* 2006; **66**: 3504-3512 [PMID: 16585174 DOI: 10.1158/0008-5472.CAN-05-0280]
- 66 **Dougherty MW**, Jobin C. Intestinal bacteria and colorectal cancer: etiology and treatment. *Gut Microbes* 2023; **15**: 2185028 [PMID: 36927206 DOI: 10.1080/19490976.2023.2185028]
- 67 **Han J**, Zhang B, Zhang Y, Yin T, Cui Y, Liu J, Yang Y, Song H, Shang D. Gut microbiome: decision-makers in the microenvironment of colorectal cancer. *Front Cell Infect Microbiol* 2023; **13**: 1299977 [PMID: 38156313 DOI: 10.3389/fcimb.2023.1299977]
- 68 **Mima K**, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Noshio K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E, Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. *JAMA Oncol* 2015; **1**: 653-661 [PMID: 26181352 DOI: 10.1001/jamaoncol.2015.1377]
- 69 **Qu R**, Zhang Y, Ma Y, Zhou X, Sun L, Jiang C, Zhang Z, Fu W. Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer. *Adv Sci (Weinh)* 2023; **10**: e2205563 [PMID: 37263983 DOI: 10.1002/advs.202205563]
- 70 **Wong CC**, Yu J. Gut microbiota in colorectal cancer development and therapy. *Nat Rev Clin Oncol* 2023; **20**: 429-452 [PMID: 37169888 DOI: 10.1038/s41571-023-00766-x]
- 71 **Liu D**, Chen S, Gou Y, Yu W, Zhou H, Zhang R, Wang J, Ye F, Liu Y, Sun B, Zhang K. Gastrointestinal Microbiota Changes in Patients With Gastric Precancerous Lesions. *Front Cell Infect Microbiol* 2021; **11**: 749207 [PMID: 34956928 DOI: 10.3389/fcimb.2021.749207]
- 72 **Xu W**, Xu L, Xu C. Relationship between *Helicobacter pylori* infection and gastrointestinal microecology. *Front Cell Infect Microbiol* 2022; **12**: 938608 [PMID: 36061875 DOI: 10.3389/fcimb.2022.938608]
- 73 **Luther J**, Owyang SY, Takeuchi T, Cole TS, Zhang M, Liu M, Erb-Downward J, Rubenstein JH, Chen CC, Pierzchala AV, Paul JA, Kao JY. *Helicobacter pylori* DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis. *Gut* 2011; **60**: 1479-1486 [PMID: 21471567 DOI: 10.1136/gut.2010.220087]
- 74 **Cui MY**, Cui ZY, Zhao MQ, Zhang MJ, Jiang QL, Wang JJ, Lu LG, Lu YY. The impact of *Helicobacter pylori* infection and eradication therapy containing minocycline and metronidazole on intestinal microbiota. *BMC Microbiol* 2022; **22**: 321 [PMID: 36581836 DOI: 10.1186/s12936-022-03860-8]

- 10.1186/s12866-022-02732-6]
- 75 **Chen CC**, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between *Helicobacter pylori* and gastrointestinal microbiota. *Gut Microbes* 2021; **13**: 1-22 [PMID: 33938378 DOI: 10.1080/19490976.2021.1909459]
- 76 **Jones TA**, Hernandez DZ, Wong ZC, Wandler AM, Guillemin K. The bacterial virulence factor CagA induces microbial dysbiosis that contributes to excessive epithelial cell proliferation in the *Drosophila* gut. *PLoS Pathog* 2017; **13**: e1006631 [PMID: 29049360 DOI: 10.1371/journal.ppat.1006631]
- 77 **Luo S**, Ru J, Mirzaei MK, Xue J, Peng X, Ralser A, Mejias-Luque R, Gerhard M, Deng L. Gut virome profiling identifies an association between temperate phages and colorectal cancer promoted by *Helicobacter pylori* infection. *Gut Microbes* 2023; **15**: 2257291 [PMID: 37747149 DOI: 10.1080/19490976.2023.2257291]
- 78 **Zhang Q**, Zhao Q, Li T, Lu L, Wang F, Zhang H, Liu Z, Ma H, Zhu Q, Wang J, Zhang X, Pei Y, Liu Q, Xu Y, Qie J, Luan X, Hu Z, Liu X. *Lactobacillus plantarum*-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8(+) T cell immunity. *Cell Metab* 2023; **35**: 943-960.e9 [PMID: 37192617 DOI: 10.1016/j.cmet.2023.04.015]
- 79 **Zhang L**, Liu J, Deng M, Chen X, Jiang L, Zhang J, Tao L, Yu W, Qiu Y. *Enterococcus faecalis* promotes the progression of colorectal cancer via its metabolite: biliverdin. *J Transl Med* 2023; **21**: 72 [PMID: 36732757 DOI: 10.1186/s12967-023-03929-7]
- 80 **Sharndama HC**, Mba IE. *Helicobacter pylori*: an up-to-date overview on the virulence and pathogenesis mechanisms. *Braz J Microbiol* 2022; **53**: 33-50 [PMID: 34988937 DOI: 10.1007/s42770-021-00675-0]
- 81 **Selgrad M**, Bornschein J, Kandulski A, Hille C, Weigt J, Roessner A, Wex T, Malfertheiner P. *Helicobacter pylori* but not gastrin is associated with the development of colonic neoplasms. *Int J Cancer* 2014; **135**: 1127-1131 [PMID: 24496701 DOI: 10.1002/ijc.28758]
- 82 **Shmueli H**, Passaro D, Figer A, Niv Y, Pitlik S, Samra Z, Koren R, Yahav J. Relationship between *Helicobacter pylori* CagA status and colorectal cancer. *Am J Gastroenterol* 2001; **96**: 3406-3410 [PMID: 11774957 DOI: 10.1111/j.1572-0241.2001.05342.x]
- 83 **Malallah Ghayemi S**, Aboutaleb N, Yousefi G, Mousavi-Niri N, Naseroleslami M. Association of D299G Polymorphism of TLR4 Gene and CagA Virulence Factor of *H. pylori* among the Iranian Patients with Colorectal Cancer. *Med J Islam Repub Iran* 2022; **36**: 96 [PMID: 36419946 DOI: 10.47176/mjiri.36.96]
- 84 **Papastergiou V**, Karatapanis S, Georgopoulos SD. *Helicobacter pylori* and colorectal neoplasia: Is there a causal link? *World J Gastroenterol* 2016; **22**: 649-658 [PMID: 26811614 DOI: 10.3748/wjg.v22.i2.649]
- 85 **Keenan JI**, Beaugie CR, Jasmann B, Potter HC, Collett JA, Frizelle FA. *Helicobacter* species in the human colon. *Colorectal Dis* 2010; **12**: 48-53 [PMID: 20050183 DOI: 10.1111/j.1463-1318.2008.01672.x]
- 86 **Kapetanakis N**, Kountouras J, Zavos C, Polyzos SA, Kouklakis G, Venizelos I, Nikolaidou C, Vardaka E, Paikos D, Katsinelos P, Romiopoulou I. *Helicobacter pylori* infection and colorectal carcinoma: pathologic aspects. *J Gastrointest Oncol* 2012; **3**: 377-379 [PMID: 23205317 DOI: 10.3978/j.issn.2078-6891.2012.041]
- 87 **Fujimori S**. Progress in elucidating the relationship between *Helicobacter pylori* infection and intestinal diseases. *World J Gastroenterol* 2021; **27**: 8040-8046 [PMID: 35068852 DOI: 10.3748/wjg.v27.i47.8040]
- 88 **Kotilea K**, Bontems P, Touati E. Epidemiology, Diagnosis and Risk Factors of *Helicobacter pylori* Infection. *Adv Exp Med Biol* 2019; **1149**: 17-33 [PMID: 31016621 DOI: 10.1007/5584_2019_357]
- 89 **Saito H**, Nishikawa Y, Masuzawa Y, Tsubokura M, Mizuno Y. *Helicobacter pylori* Infection Mass Screening for Children and Adolescents: a Systematic Review of Observational Studies. *J Gastrointest Cancer* 2021; **52**: 489-497 [PMID: 33761050 DOI: 10.1007/s12029-021-00630-0]
- 90 **Xu X**, Li W, Qin L, Yang W, Yu G, Wei Q. Relationship between *Helicobacter pylori* infection and obesity in Chinese adults: A systematic review with meta-analysis. *PLoS One* 2019; **14**: e0221076 [PMID: 31509542 DOI: 10.1371/journal.pone.0221076]
- 91 **Alarfaj SJ**, Abdallah Mostafa S, Abdelsalam RA, Negm WA, El-Masry TA, Hussein IA, El Nakib AM. *Helicobacter pylori* Infection in Cirrhotic Patients With Portal Hypertensive Gastropathy: A New Enigma? *Front Med (Lausanne)* 2022; **9**: 902255 [PMID: 35801205 DOI: 10.3389/fmed.2022.902255]
- 92 **Liu Y**, Li R, Xue X, Xu T, Luo Y, Dong Q, Liu J, Pan Y, Zhang D. Periodontal disease and *Helicobacter pylori* infection in oral cavity: a meta-analysis of 2727 participants mainly based on Asian studies. *Clin Oral Investig* 2020; **24**: 2175-2188 [PMID: 32474810 DOI: 10.1007/s00784-020-03330-4]
- 93 **Zhuang Z**, Yu B, Xie M, Zhang Y, Lv B. Association of *Helicobacter pylori* enrichment in colorectal adenoma tissue on clinical and pathological features of adenoma. *Clin Res Hepatol Gastroenterol* 2022; **46**: 101961 [PMID: 35636682 DOI: 10.1016/j.clinre.2022.101961]
- 94 **Iwai K**, Azuma T, Yonenaga T, Watanabe K, Obora A, Deguchi F, Kojima T, Tomofuji T. Association between dental caries and *Helicobacter pylori* infection in Japanese adults: A cross-sectional study. *PLoS One* 2022; **17**: e0271459 [PMID: 35834591 DOI: 10.1371/journal.pone.0271459]
- 95 **Dong YF**, Guo T, Yang H, Qian JM, Li JN. [Correlations between gastric *Helicobacter pylori* infection and colorectal polyps or cancer]. *Zhonghua Nei Ke Za Zhi* 2019; **58**: 139-142 [PMID: 30704201 DOI: 10.3760/cma.j.issn.0578-1426.2019.02.011]
- 96 **Sonnenberg A**, Genta RM. *Helicobacter pylori* is a risk factor for colonic neoplasms. *Am J Gastroenterol* 2013; **108**: 208-215 [PMID: 23208272 DOI: 10.1038/ajg.2012.407]
- 97 **Wang M**, Kong WJ, Zhang JZ, Lu JJ, Hui WJ, Liu WD, Kang XJ, Gao F. Association of *Helicobacter pylori* infection with colorectal polyps and malignancy in China. *World J Gastrointest Oncol* 2020; **12**: 582-591 [PMID: 32461789 DOI: 10.4251/wjgo.v12.i5.582]
- 98 **Yang W**, Yang X. Association between *Helicobacter pylori* Infection and Colorectal Adenomatous Polyps. *Gastroenterol Res Pract* 2019; **2019**: 7480620 [PMID: 31929786 DOI: 10.1155/2019/7480620]
- 99 **Wang C**, Yan J, He B, Zhang S, Xu S. Hp-Positive Chinese Patients Should Undergo Colonoscopy Earlier and More Frequently: The Result of a Cross-Sectional Study Based on 13,037 Cases of Gastrointestinal Endoscopy. *Front Oncol* 2021; **11**: 698898 [PMID: 34513677 DOI: 10.3389/fonc.2021.698898]
- 100 **Breuer-Katschinski B**, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N, Goebell H. *Helicobacter pylori* and the risk of colonic adenomas. Colorectal Adenoma Study Group. *Digestion* 1999; **60**: 210-215 [PMID: 10343134 DOI: 10.1159/000007661]
- 101 **Guo Y**, Li HY. Association between *Helicobacter pylori* infection and colorectal neoplasm risk: a meta-analysis based on East Asian population. *J Cancer Res Ther* 2014; **10** Suppl: 263-266 [PMID: 25693932 DOI: 10.4103/0973-1482.151482]
- 102 **Teimoorian F**, Ranaei M, Hajian Tilaki K, Shokri Shirvani J, Vosough Z. Association of *Helicobacter pylori* Infection With Colon Cancer and Adenomatous Polyps. *Iran J Pathol* 2018; **13**: 325-332 [PMID: 30636955]
- 103 **Lu D**, Wang M, Ke X, Wang Q, Wang J, Li D. Association Between *H. pylori* Infection and Colorectal Polyps: A Meta-Analysis of Observational Studies. *Front Med (Lausanne)* 2021; **8**: 706036 [PMID: 35118081 DOI: 10.3389/fmed.2021.706036]
- 104 **Zhao XX**, Liu MH, Wang RL, Tian T. Effect of Gender and Age on the Correlation between *Helicobacter pylori* and Colorectal Adenomatous

- Polypos in a Chinese Urban Population: A Single Center Study. *Gastroenterol Res Pract* 2020; **2020**: 8596038 [PMID: 32104172 DOI: 10.1155/2020/8596038]
- 105 **Hong SN**, Lee SM, Kim JH, Lee TY, Choe WH, Lee SY, Cheon YK, Sung IK, Park HS, Shim CS. Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. *Dig Dis Sci* 2012; **57**: 2184-2194 [PMID: 22669208 DOI: 10.1007/s10620-012-2245-x]
- 106 **Kim HS**, Baik SJ, Kim KH, Oh CR, Lee SI. [Prevalence and risk factors of colorectal adenoma in 14,932 Koreans undergoing screening colonoscopy]. *Korean J Gastroenterol* 2013; **62**: 104-110 [PMID: 23981944 DOI: 10.4166/kjg.2013.62.2.104]
- 107 **Wang F**, Sun MY, Shi SL, Lv ZS. Helicobacter pylori infection and normal colorectal mucosa-adenomatous polyp-adenocarcinoma sequence: a meta-analysis of 27 case-control studies. *Colorectal Dis* 2014; **16**: 246-252 [PMID: 23692360 DOI: 10.1111/codi.12290]
- 108 **Kumar A**, Kim M, Lukin DJ. Helicobacter pylori is associated with increased risk of serrated colonic polyps: Analysis of serrated polyp risk factors. *Indian J Gastroenterol* 2018; **37**: 235-242 [PMID: 29876742 DOI: 10.1007/s12664-018-0855-8]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

